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Abstract
Background: Trials in school-aged children suggest vitamin D supplementation reduces asthma exacerbations.
Primary aim: to examine whether vitamin D3 (100,000 IU) rapidly raises serum 25-hydroxyvitamin D (25OHD)
≥75 nmol/L in asthmatic preschoolers.
Methods: In a double-blind, randomised, placebo-controlled trial, preschool-aged children with asthma received
100,000 IU vitamin D3 (intervention) or placebo (control), followed by 400 IU vitamin D3 daily for 6 months. Serum
25OHD was measured at baseline, 10 days, 3 and 6 months. Outcomes included the group difference in 25OHD
change from baseline at 3 months (Δ25OHD); the proportion of children with 25OHD ≥75 nmol/L at 3 months; the
pattern in serum vitamin D over 6 months; the proportion of children with hypercalciuria at any time point (safety);
and group rates for oral corticosteroids. Continuous outcomes were analysed using generalised linear mixed
models and group rate ratios of events per child were assessed using a Poisson distribution model.
Results: Twenty-two children were randomised (intervention:11; control:11) during winter. At 3 months, the group
difference in Δ25OHD (7.2 nmol/L; 95 % CI: -13.7, 28.1) was not significant; yet, 100 % versus 54.5 % (intervention
versus control) had serum 25OHD ≥75 nmol/L. There was a significant group difference in Δ25OHD at 10 days (110.
3 nmol/L; 95 % CI: 64.0, 156.6). One child in each group had transient hypercalciuria at 10 days. Group oral
corticosteroids rates were 0.82 and 1.18/child, intervention versus control (rate ratio = 0.68; 95 % CI: 0.30, 1.62; non-
significant).
Conclusions: Following 100,000 IU vitamin D3, all children reached serum 25OHD ≥75 nmol/L, compared with half
who received placebo. Daily supplementation, sun exposure and insufficient power may explain the absence of a
significant 3-month group difference in Δ25OHD. No clinically important alterations in bone metabolism biomarkers
occurred. Group oral corticosteroid rates will inform sample size calculations for the larger trial. (NCT01999907,
25 November 2013).
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Background
Preschoolers experience significant morbidity due to
asthma and have the highest rate of emergency depart-
ment visits attributable to asthma [1], with a notable
proportion hospitalised following an acute care visit
[2]. This is not surprising considering wheeze, the most
common symptom associated with asthma in pre-
schoolers [3], affects up to 50 % of children before age
six [4]. More than 80 % of asthma exacerbations in
children are triggered by viral upper respiratory tract
infections (URTIs) [5]. URTIs occur at a rate of up to
eight per year in preschoolers with recurrent wheeze or
asthma [6, 7], the most common being rhinovirus [5].
It is therefore pertinent to explore preventive strategies
to reduce the frequency and severity of viral-induced
asthma exacerbations in preschool-aged children.
To date, pharmacological therapeutic avenues have pre-
dominantly been explored. Daily low-dose inhaled cortico-
steroids (ICS) and pre-emptive high-dose ICS are both
effective in reducing the frequency of moderate to severe
exacerbations requiring rescue oral corticosteroids [8, 9].
Uncertainties about the diagnosis and worry about side
effects have limited the uptake of both strategies by physi-
cians and/or parents. In paediatric observational studies,
circulating 25-hydroxyvitamin D (25OHD) has been in-
versely associated with asthma severity, ICS dose, and the
number of exacerbations requiring rescue oral cortico-
steroids or health care utilisation [10–12], as well as
increased risk of viral URTIs [13]. In three placebo-
controlled randomised trials of school-aged children
with asthma, daily [14, 15] or monthly [16] vitamin D
supplementation significantly reduced the rate of mild
(requiring rescue short-acting β2-agonists, SABA) [14,
15] and moderate (requiring an acute care visit) [16]
asthma exacerbations, with most exacerbations report-
edly preceded by URTIs [14, 15]. Although it has not
yet been investigated in preschool-aged children with
recurrent viral-induced exacerbations, vitamin D sup-
plementation appears promising to decrease the fre-
quency of asthma exacerbations. Moreover, the use of a
large dose administered by a health care professional,
as opposed to daily supplementation, is likely to rapidly
increase serum 25OHD levels to the desired target and
remove the issue of non-compliance associated with
patient-administered supplementation.
The aim of this pilot randomised controlled trial (RCT)
was to investigate whether a single large dose of vitamin
D3 effectively raises serum 25OHD to levels considered
sufficient for potential extra-skeletal benefits (≥75 nmol/L
[≥30 ng/mL]) [17, 18], in preschool-aged children with
viral-induced asthma, compared with placebo. Second, we
aimed to assess the feasibility of recruitment, intervention,
procedures, and follow-up, and obtain pilot efficacy and
safety data to inform the design of a large RCT.
Methods
Trial design
We conducted a 6-month randomised, parallel-group,
double-blinded, placebo-controlled pilot trial of vitamin
D3 (cholecalciferol) supplementation in preschool-aged
children with viral-induced asthma. Patients were re-
cruited in the asthma clinic, hospital wards, and emer-
gency department of the Sainte-Justine University Health
Centre, Montreal, QC, Canada, during the winter months,
November 2013 to February 2014. The study was approved
by the Sainte-Justine University Health Centre Research
Ethics Board (#3760) and registered on ClinicalTrials.gov
(NCT01999907, November 2013). Written informed con-
sent was obtained from parents prior to their child’s
participation.
Participants
Children aged 1–5 years were eligible if they had: (i)
physician-diagnosed asthma, based on clinical signs of
airflow obstruction and reversibility [3, 19]; (ii) URTIs as
the main exacerbation trigger, reported by parents; (iii) ≥4
parent-reported URTIs in the past 12 months; and (iv) ≥1
exacerbation requiring oral corticosteroids in the past
6 months or ≥2 in the past 12 months. Exclusion criteria
included: extreme prematurity (<28 weeks’ gestation); high
risk of vitamin D deficiency; other chronic respiratory dis-
ease; disordered calcium or vitamin D metabolism; oral
medications interfering with vitamin D metabolism; or
vitamin D supplementation greater than 1000 IU/day in
the past 3 months.
Interventions and procedures
Additional file 1 details the study design and schedule
of procedures. At baseline, subjects received orally
2 mL of either 50,000 IU/mL vitamin D3 or identical
placebo (Euro-Pharm International Canada, Montreal,
QC, Canada). The dose was administered by the nurse,
followed by 30 minutes of monitoring. The investiga-
tors initially believed it was unethical to not provide
vitamin D to the control group, who were suspected to
have low serum 25OHD levels at recruitment; thus, all
participants, irrespective of group assignment, were
provided with Pediavit D400 (Euro-Pharm International
Canada, Montreal, QC, Canada) and instructed to take
1 mL daily (400 IU vitamin D3) during the study. Adher-
ence was assessed by weighing the bottles before dispensa-
tion and at their return at each clinic visit.
Patient characteristics were documented at baseline,
including skin type [20] and asthma control [21]. Non-
fasting blood and urine samples were collected at base-
line, 10 days (±3 days), 3 and 6 months (±0.5 months).
With the exception of baseline samples, which were ana-
lysed immediately, serum aliquots preserved for vitamin
D analysis were stored at -80 °C for batch analysis at the
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end of the study to maintain blinding. Total 25OHD
(comprised of 25OHD2, 25OHD3 and 3-epimer-25OHD3)
was analysed via tandem mass spectrometry [22]. Safety
biomarkers were analysed immediately using standard
laboratory processes.
Within 2 days of symptom onset (runny or congested
nose, fever, or cough), parents collected a nasal secretion
sample from the child’s nostril using a flocked mid-
turbinate swab, which was then placed in a tube containing
1 mL Universal Transport Medium (Copan Italia, Brescia,
Italy). The swab was transported by courier for storage at
-80 °C before polymerase chain reaction (PCR) analysis [23]
for 26 viruses (Laval University, Quebec City, QC, Canada).
Parents also completed three questionnaires: the Canadian
Acute Respiratory Illness and Flu Scale (CARIFS) [24]; the
Asthma Flare-up Diary for Young Children (ADYC) [25];
and the Effects of an Asthma Flare-up on the Parents
(ECAP) [26].
Randomisation and blinding
Using computer-generated randomisation with variable
block sizes of 2–4, participants were randomised 1:1 to
the intervention or control group. Group assignment,
recorded on a sequentially numbered list, was allocated
by the Sainte-Justine Hospital Research Pharmacy, which
held the randomisation code. To maintain blinding, the
intervention and placebo dose were identical in colour,
appearance, volume, taste, and packaging. All research
personnel, physicians, nurses, participants and their
parents were blinded to group allocation.
Outcomes
The primary outcome was the mean group change in total
serum 25OHD from baseline (Δ25OHD) to 3 months. Sec-
ondary outcomes were the group difference in the propor-
tion of children with total 25OHD ≥75 nmol/L (30 ng/mL)
at 3 months and in total 25OHD values over 6 months.
Exploratory outcomes included: (i) safety measures,
namely the proportion of children with hypercalciuria
(urinary calcium: creatinine ratio (Ca:Cr) >1.25 (1–2
years) and >1 (2–5 years) mmol/mmol) [27] at any time
point, serum calcium, phosphorus, and alkaline phos-
phatase (ALP) [28]; and (ii) event rates for exacerbations
requiring rescue oral corticosteroids (documented in
medical and/or pharmacy records).
Sample size
As prior information on the standard deviation for the
change in total serum 25OHD was not available, the
sample size was based on the expected proportion of
patients with 25OHD ≥75 nmol/L (30 ng/mL) at
3 months, as reported in a previous study where 100 %
of the intervention versus 55 % of the control subjects
achieved a serum 25OHD level ≥75 nmol/L (30 ng/mL)
[29]. Fifteen children per group were required to achieve
80 % power to detect a difference between the group
proportions of 0.45, using a two-sided Mantel-Hansel
test with alpha of 0.05. Allowing for a 10 % drop-out
rate, we aimed to recruit 17 per group.
Statistical methods
The change in serum 25OHD profile over the 6-month
period was assessed using a generalised linear mixed
model, which included as predictors: time, group, and a
time*group interaction term. Covariates considered a
priori for inclusion in the model were those with a
distribution imbalance at baseline or a potential for con-
founding, such as baseline asthma classification (episodic
versus persistent), asthma treatment, and dietary vitamin
D. The mean group difference in Δ25OHD was reported
with 95 % confidence interval (CI). Group rate ratios of
events per child (RR) with 95 % CI were assessed using a
Poisson distribution model. A two-sided p value ≤5 %
was considered statistically significant. No adjustment
for testing multiple outcomes was made. Analyses were
conducted using SPSS® 21 (IBM SPSS Statistics, IBM
Corp., Armonk, NY, USA) and SAS® 9.3 (SAS Institute,
Cary, NC, USA).
Results
Between November 2013 and February 2014, 85 children
were screened: 45 were ineligible, primarily due to an in-
sufficient number of oral corticosteroids (55.6 %) in the
preceding year. Twenty-two children were randomised
to the intervention (N = 11) or control group (N = 11)
(Additional file 2). The trial was terminated before
reaching the target sample size, as funding was received
to commence the larger definitive trial. Retention in the
intervention versus control group was 91 % vs. 100 % at
3 months, and 73 % vs. 91 % at 6 months.
Baseline characteristics were similar between the groups,
with the exception of a higher prevalence of eczema, and a
trend towards more persistent asthma and poorer asthma
control in the control versus intervention group (Table 1).
Baseline serum 25OHD was comparable between the inter-
vention and control group (62.0 [50.0, 75.0] vs. 68.0 [50.0,
75.0] nmol/L), with the majority (n = 8, 72.7 %) in each
group displaying baseline values <75 nmol/L (30 ng/mL);
none were in the potentially rachitic range (<25 nmol/L
[10 ng/mL]).
Median daily dietary intake of vitamin D was markedly
below the recommended 600 IU [30] in the intervention
[356.0 (161.0, 510.0)] and control group [189.0 (166.0,
281.0)] at baseline. Dietary intake of vitamin D did not
change significantly at 3 or 6 months in the intervention
[274.0 (202.8, 601.5); 284.0 (157.0, 296.0)] or control
group [198.0 (163.5, 283.5); 155.0 (134.0, 217.5)].
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Adherence with the study bolus (100,000 IU vitamin D3/
placebo) dose was 100 %. Most participants (65–80 %)
returned the vitamin D bottles for weighing; median adher-
ence was >92 % in both groups. The group difference in
Δ25OHD was not statistically significant at 3 months
(7.2 nmol/L; 95 % CI: -13.7, 28.1); however, 100 % of chil-
dren in the intervention group, compared to 54.5 % of the
control group, had vitamin D levels ≥75 nmol/L (p = 0.035).
There was a statistically significant change in the mean total
25OHD over the 6 months (p ˂0.001), with a significant
group, time, and group*time interaction effect (Additional
file 3). Skin colour (p = 0.041) and the interaction between
visit and asthma classification (p = 0.007) were significant
variables in the model; conversely, parent-reported median
daily sun exposure or season of measurement, which did
not differ between groups, were not significant covariates.
At 10 days, the within-group Δ25OHD was statistically
significant for the intervention, but not the control group
[132.5 (95 % CI: 100.4, 164.7) vs. 22.2 (-10.5, 55.0) nmol/L],
with a significant between-group difference [110.3 (64.0,
156.6) nmol/L]. The within-group Δ25OHD was statisti-
cally significant at both 3 and 6 months in the intervention
[27.1 (12.7, 41.4); 34.4 (21.7, 47.0) nmol/L] and control
groups [19.8 (5.2, 34.5); 22.2 (10.5, 34.0) nmol/L]; but there
were no between-group differences. The unadjusted values
for serum 25OHD are presented in Additional file 4.
Two patients in the intervention group had an ele-
vated total 25OHD (>225 nmol/L [90 ng/mL]) at 10 days
(236 and 358 nmol/L); in both cases, the urinary Ca:Cr
was normal. One child in the intervention group had
hypercalciuria at 10 days, and one child in the control
group had hypercalciuria at baseline and 10 days; none
were associated with an elevated 25OHD value (196, 67
and 83 nmol/L, respectively) or hypercalcemia. There
were several minor fluctuations in serum calcium,
phosphorus and ALP, in both groups over the 6 months
(Additional file 5); none were of clinical significance.
No serious clinical or laboratory adverse health events
occurred.
The rate of URTIs per patient month of follow-up did
not differ between the intervention and control group
[0.53 vs. 0.67; RR 0.74 (95 % CI: 0.46, 1.17)]; with 70.8 %
(intervention) and 76.0 % (control) confirmed positive
for at least one virus. The rate of acute-care visits [0.64
vs. 0.73; RR 0.88 (95 % CI: 0.32, 2.41)] and oral cortico-
steroids [0.82 vs. 1.18; RR 0.68 (95 %CI: 0.30, 1.62)] per
child was not significantly different between the inter-
vention and control group; one hospital admission
occurred in the control group only.
Discussion
This pilot RCT demonstrated the feasibility of an oral
dose of 100,000 IU vitamin D3 to achieve vitamin D
sufficiency at 3 months in all intervention patients,
compared to about half of those allocated placebo. This
observation did not translate into a statistically signifi-
cant group difference in the change in total serum
25OHD from baseline to 3 months, although signifi-
cantly more intervention children achieved vitamin D
sufficiency at 3 months. Bone metabolism biomarkers
provide preliminary data on the safety of the interven-
tion, while the observed group rate of exacerbations
requiring oral corticosteroids informs power calcula-
tions for the full-scale trial.
With approximately three-quarters of participants vita-
min D-insufficient at baseline, 100,000 IU of vitamin D3
was effective in rapidly raising total serum 25OHD by
10 days and maintaining vitamin D sufficiency at 3 months
in 100 % of the intervention group, compared to barely
half of those assigned to the placebo. This rapid rise in
serum 25OHD has previously been demonstrated in one
infant [31] and one adolescent trial [32], 15 days following
100,000 and 200,000 IU, respectively, of oral vitamin D3.
Concordant with a prior trial reporting 55 % of those re-
ceiving 400 IU daily vitamin D3 achieved 25OHD levels
≥75 nmol/L (30 ng/mL) at 3 months [29], our data suggest
that, while daily 400 IU in addition to current dietary
intake (approximately 200 IU) prevents the expected
serum 25OHD decline in the fall and winter (with signifi-
cant within-group increases at 3 and 6 months in the





Age (years) 2.2 (1.9, 3.5) 3.1 (2.1, 3.9)
Male gender 4 (36.4 %) 3 (27.3 %)
Caucasian ethnicity* 5 (45.5 %) 8 (72.7 %)
Asthma control (Asthma
Quiz for Kidz [20]), score
1.00 (0.00, 3.00) 4.00 (0.00, 6.00)
Asthma classification: Persistent 5 (45.5 %) 8 (72.7 %)
Episodic 6 (54.5 %) 3 (27.3 %)
Trigger of asthma: Multitrigger 3 (27.3 %) 4 (36.4 %)
Unitrigger 8 (72.7 %) 7 (63.6 %)
Eczema 8 (72.7 %) 2 (18.2 %)
Daycare attendance 9 (81.8 %) 11 (100 %)
Parent-reported URTIs in the
past 12 months, number
6.0 (5.0, 12.0) 5.0 (4.0, 10.0)
Oral corticosteroid courses in the
past 12 months, number
2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Influenza vaccine received 5 (45.5 %) 5 (45.5 %)
Preventer asthma medication:
Episodic ICS
2 (18.2 %) 2 (18.2 %)
Daily ICS ± anti-leukotrienes 8 (72.7 %) 9 (81.8 %)
Results are reported as median (25 %, 75 %) or n (%)
URTI upper respiratory tract infection, ICS, inhaled corticosteroid
*Other ethnicities: Maghreb (9.1 %), Mixed (9.1 %), Latino (9.1 %), Arab (9.1 %),
Asian (4.5 %)
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control group), it is insufficient to achieve vitamin D levels
≥75 nmol/L (30 ng/mL) in control patients. Yet, our main
endpoint, group difference in the change in total 25OHD
from baseline to 3 months, was not statistically significant.
This non-separation of the groups was likely due to one,
or a combination, of three main factors: (i) daily vitamin
D3 supplementation in the control group; (ii) increased
opportunity for ultraviolet B exposure [17], as more than
half of the 3-month visits occurred in the spring; and (iii)
our small sample size. In future trials, we would recom-
mend the dose of 100,000 IU vitamin D3 be administered
in early fall or winter, to pre-empt the expected seasonal
decline in 25OHD and minimise the influence of sun
exposure in spring and summer [17], and removal of daily
vitamin D3 supplementation in the control group.
Although not powered to firmly conclude, our results
contribute data supporting the safety of a dose of
100,000 IU vitamin D3 in preschool-aged children with
asthma; there were no cases of potentially toxic 25OHD
levels [18] or clinically significant changes in bone me-
tabolism biomarkers. Of the five paediatric trials testing
repeated oral doses of 100,000 IU vitamin D [31, 33–36],
all but one measured circulating 25OHD [36]; just one
trial reported two cases (0.3 %) of 25OHD >375 nmol/L
(150 ng/mL) in a population of malnourished infants
[36], but did not measure serum or urine bone metabol-
ism biomarkers [35, 36], such that the clinical signifi-
cance of the findings is unclear. Hence, only three of the
five aforementioned trials provided additional safety data
for a total of 15 infants [31] and 47 school-aged children
and adolescents [33, 34]. Of these, one found ALP signifi-
cantly decreased 9 months after study initiation in infants
[31], and another reported one transient hypercalciuria
event in the placebo group [34]; neither were clinically im-
portant alterations. Likewise, the few hypercalciuria events,
documented in one subject of each group in our study,
were transient. Occasional minor deviations from normal
laboratory values were likely due to the non-fasting status
of our patients, in contrast to a trial where subjects fasted
[37]. While the administration of two spaced doses of
80,000–100,000 IU vitamin D every winter is recom-
mended for all preschool-aged children in France [38], the
evidence supporting the safety profile of this approach is
weak and thus requires confirmatory data to be adopted in
practice in North America. In future trials, we recommend
the documentation of circulating 25OHD and bone metab-
olism biomarkers, including fasting urinary calcium:creati-
nine, in all subjects, with greater power to contribute data
regarding the safety of a high-dose vitamin D3 oral bolus.
Our trial also aimed to provide health event rates to
inform sample size calculations for the subsequent
large-scale trial. The observed trend towards a 32 %
reduction in the rate of exacerbations requiring oral
corticosteroids with high-dose vitamin D3 is promising,
but is not statistically significant. In three placebo-
controlled RCTs of school-aged children with asthma,
vitamin D supplementation has significantly reduced
the rate of mild (requiring only rescue β2-agonists) to
moderate (requiring emergency visits) asthma exacerba-
tions by 64 % (RR: 0.36) with 500 IU/ day for 6 months
[14], by 83 % (RR: 0.17) with 1200 IU/ day for 4 months
[15], and by 53 % (RR: 0.47) with 60,000 IU monthly for
6 months [16]. Although the optimal delay between doses
remains to be confirmed, repeat dosing in the context of a
longer intervention period may be needed to increase the
duration of vitamin D sufficiency, and thus maximise the
likelihood of vitamin D supplementation benefit. Vitamin
D may reduce asthma exacerbations via improving resist-
ance to viral infections [39] (a main trigger of asthma
exacerbations) [5], modulating the inflammatory response
[40], either directly or indirectly by improving response to
corticosteroid maintenance medications, or relaxation of
bronchial smooth muscle [41]. The observed trend to-
wards fewer exacerbations warrants further investigation
in trials adequately powered to detect a statistically signifi-
cant group difference in this important health outcome
for children with asthma.
This study has several notable aspects, namely, dose
administration by research personnel in the routine
clinical setting, which achieved 100 % compliance and
avoided the potential non-compliance associated with
self-administered daily supplementation [15, 29]. Im-
portantly, there was no clinically important change in
dietary vitamin D intake over the 6-month period, in-
dicating no evidence of Hawthorne bias; that is, par-
ticipation in the study did not lead to higher dietary
intake of vitamin D in either group. In addition, we
used the gold-standard method, tandem mass spectro-
photometry, to quantify serum vitamin D3, including
epimer-D3. The documentation of several bone metab-
olism biomarkers offers preliminary data towards the
safety of this supplementation dose.
We acknowledge several limitations to this trial, namely,
being underpowered for our specified primary outcome,
which possibly impaired our ability to firmly conclude on
our main outcome. However, we detected a statistically
significant difference in the proportion of children with
vitamin D sufficiency, our secondary outcome, from which
our sample size was calculated. It is also possible that the
period during which children maintained vitamin D suffi-
ciency was not sufficient to allow the proposed effects of
vitamin D to be observed; thus, a longer intervention, with
repeat dosing, may be warranted. As the administration of
daily 400 IU in both groups probably prevented group
separation, future studies could consider removal of daily
supplementation in the control group alone to maximise
group separation. Indeed, a recent review suggests that
daily vitamin D supplementation may be more effective
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than bolus dosing in reducing respiratory tract infections
[42], and the potential for adverse effects of rapid shifts in
local tissue 1,25OHD levels induced by bolus dosing has
been proposed [43]. This has led to some suggestion that
more regular supplementation of vitamin D could be a
preferred regimen, e.g. daily or weekly, with or without
bolus dosing, to more smoothly elevate and maintain
serum 25OHD; however, one must consider in their
design the time it would take to reach the target level of
75 nmol/L (intervention would need to be started months
prior to the desired period for anticipated effect) and
the compliance issues with placing the burden of
supplementation on the parent/carer. Regardless of
treatment regimen, the evidence to date suggests that
vitamin D supplementation may be more effective in
improving asthma outcomes in the paediatric popula-
tion as opposed to adults [44], and ours is the first trial
to examine the use of a bolus vitamin D dose in chil-
dren with asthma. In terms of compliance and rapidly
attaining a serum 25OHD level >75 nmol/L, the bolus
dose appears ideal.
Our group included both children with persistent and
episodic asthma. One may hypothesise that the response
to vitamin D potentially differs between these groups.
However, even amongst asthma specialists, there is not-
able intra-patient and between-physician variability in
classification [45, 46], due to third-party reporting of
symptoms and the inability to obtain standard lung
function tests in preschoolers; thus, we acknowledge that
the accuracy of this classification is debatable. We also
acknowledge that some would hesitate to definitively
diagnose asthma in children <2 years of age, instead
classing this group as ‘early wheezers’; however, we ap-
plied the Canadian guidelines for asthma diagnosis in
preschoolers (i.e. observed obstruction and reversibility)
for inclusion in the study [19]. Although our small sam-
ple size did not allow stratification of analyses to exam-
ine whether vitamin D response differed by age group or
asthma classification, this is an interesting consideration
for future trials.
Conclusions
This pilot study confirmed the feasibility and effectiveness
of the intervention to rapidly raise total serum 25OHD
and correct vitamin D insufficiency; however, our study
was underpowered to detect a significant group difference
in Δ25OHD at 3 months. With no cases of a toxic serum
25OHD value or clinically important alteration in key
biomarkers, our data inform, but do not prove, the safety
of the intervention. Our results provide promising data
with a non-significant trend towards a reduction in the
rate of rescue oral corticosteroids in the intervention
group, which underlines the need for a large-scale trial.
The ideal design to test the efficacy of high-dose vitamin
D3 should include the administration of the dose early in
the fall or winter, without concurrent daily vitamin D
supplementation.
Additional files
Additional file 1: Study design and procedures. *Asthma Quiz for Kidz
[20], a 6-item questionnaire, where a score of two or more indicates poor
asthma control. ‡A 3-item questionnaire, developed ad hoc. ∫A visual
paediatric tool, developed ad hoc, adapted from the validated adult
Fitzpatrick scale [19]. ∫Food checklists developed by dietitian (MEJ).
¶Asthma Flare-up Diary for Young Children [24]; Canadian Acute
Respiratory Infection and Flu Scale [23]; and Effect of a Young Child’s
Asthma Flare-up on the Parent questionnaires [25]. ||URTI, upper
respiratory tract infection. **ALP, alkaline phosphatase. (PDF 73 kb)
Additional file 2: Patient selection and retention. The number of
children included at screening, randomisation, follow-up and analysis are
presented for the 6-month study. *Children had less than one rescue oral
corticosteroid course in the past 6 months, or less than two in the previous
12 months. †Children had less than four parent-reported upper respiratory
tract infections (URTIs) in the past 12 months. ‡Lost to follow-up before
3-month visit. ∫Withdrew before 6-month visit (n = 1 relocation; n = 2
protocol burden). (TIF 61 kb)
Additional file 3: Serum 25-hydroxy vitamin D levels over 6 months.
The estimated marginal means for total serum 25-hydroxy vitamin D
(25OHD) are presented, by group, over the 6-month study period. Error
bars represent the 95 % confidence interval around the mean. The dotted
line at 75 nmol/L (30 ng/mL) on the y-axis indicates the cut point
between proposed vitamin D sufficiency and insufficiency. (TIF 189 kb)
Additional file 4: Unadjusted serum 25-hydroxy vitamin D values over
6 months. The unadjusted values for total serum 25-hydroxy vitamin D
(25OHD) are presented, by group, over the 6-month study period. Individual
data points are represented, with the mean indicated by the straight line.
The dotted line at 75 nmol/ L (30 ng/mL) on the y-axis indicates the cut
point between proposed vitamin D sufficiency and insufficiency. (TIF 259 kb)
Additional file 5: Safety biomarkers over 6 months. The non-fasting
values for: (A) urinary calcium: creatinine, (B) serum calcium, (C) serum
alkaline phosphatase, and (D) serum phosphorous, are presented as
box-and-whiskers (Tukey) plots, by group, over the 6-month study period.
Outliers are represented by ‘*’. Reference laboratory values for given age
groups are presented by the dotted and dashed lines in each graph: [25]
A Dotted line represents upper limit (1.25) for ages 1–2 years, and
dashed line represents upper limit (1.00) for ages 2–5 years. B Dashed
lines represent upper (2.62) and lower (2.3) limit for ages 0–18 years.
C Dashed lines represent upper (369) and lower (156) limit for ages
1–9 years. D Dotted line represents upper (1.47) and lower limit (1.03)
for ages 5–12 years, and dashed line represents upper (1.7) and lower
(1.08) limit for ages 1–4 years. (TIF 584 kb)
Abbreviations
25OHD, 25-hydroxyvitamin D; ADYC, Asthma Flare-up Diary for Young
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